FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287248904> ?p ?o ?g. }

• W4287248904 endingPage "468" @default.
• W4287248904 startingPage "455" @default.
• W4287248904 abstract "BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide 1 (GLP-1) receptor agonist to be approved in the United States for glycemic control in people with type 2 diabetes mellitus (T2DM). While oral semaglutide is not indicated for reduction of cardiovascular event risk, its label does include evidence of no increase in cardiovascular risk in people who received oral semaglutide. OBJECTIVE: To estimate the incremental value of oral semaglutide added to existing antihyperglycemic treatment for people with T2DM with additional risk for cardiovascular disease. METHODS: We estimated the lifetime cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for T2DM using a microsimulation model based primarily on the UK Prospective Diabetes Study (UKPDS) Outcomes Model 2 (OM2) equations. Oral semaglutide added to current antihyperglycemic treatment was separately compared with (a) ongoing background antihyperglycemic treatment, (b) sitagliptin, (c) empagliflozin, and (d) liraglutide. Comparators sitagliptin, empagliflozin, and liraglutide were added to ongoing antihyperglycemic treatment. We applied hazard ratios derived from a network meta-analysis for cardiovascular and renal outcomes to the UKPDS OM2 estimated baseline rates. Health state utilities and costs were derived from the published literature. We estimated total costs, life-years (LYs), quality-adjusted life-years (QALYs), clinical events, and cost per major adverse cardiovascular event (MACE) avoided, over a lifetime time horizon using discount rates of 3% for costs and outcomes. RESULTS: The lifetime total cost for people treated with oral semaglutide was $311,300, with costs for the other comparators ranging from $262,800 (background treatment alone) to $287,800 (liraglutide). Oral semaglutide resulted in the fewest MACE, including the fewest cardiovascular deaths. Among the 5 modeled treatment strategies, oral semaglutide had the highest LYs gained (8.43 vs. 7.76 [background treatment alone] to 8.29 [empagliflozin and liraglutide]) and the highest QALYs gained (4.11 vs. 3.70 [background treatment alone] to 4.03 [empagliflozin]). Oral semaglutide would likely be considered cost-effective compared with liraglutide (incremental cost-effectiveness ratio [ICER] = $40,100), and moderately cost-effective versus background treatment alone ([ICER] = $117,500/QALY) and sitagliptin (ICER = $145,200/QALY). The ICER for oral semaglutide compared with empagliflozin was approximately $458,400 per QALY. CONCLUSIONS: As modeled, oral semaglutide as an add-on therapy to background antihyperglycemic treatment produced incremental benefits in MACE avoided, along with greater QALYs compared with background antihyperglycemic treatment alone. Oral semaglutide use resulted in better outcomes than background treatment alone or sitagliptin, and similar outcomes to liraglutide or empagliflozin with overlapping 95% confidence ranges for QALYs. Oral semaglutide was estimated to be cost-effective compared with liraglutide and to have incremental cost-effectiveness ratios between $100,000 and $150,000 per QALY versus sitagliptin and background therapy alone, but it did not meet these thresholds compared with empagliflozin. DISCLOSURES: Funding for this study was provided by the Institute for Clinical and Economic Review, an independent organization that evaluates the evidence on the value of health care interventions. ICER reports grants from Laura and John Arnold Foundation, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan. ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Rind, Fazioli, Chapman, and Pearson are employed by ICER. Guzauskas and Hansen have nothing to disclose. Study results were presented at the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), November 14, 2019, at Brown University, Providence, RI." @default.
• W4287248904 created "2022-07-25" @default.
• W4287248904 creator A5013185975 @default.
• W4287248904 creator A5056528203 @default.
• W4287248904 creator A5073846586 @default.
• W4287248904 creator A5078803157 @default.
• W4287248904 creator A5083493729 @default.
• W4287248904 creator A5085357003 @default.
• W4287248904 date "2021-04-01" @default.
• W4287248904 modified "2023-09-29" @default.
• W4287248904 title "Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes." @default.
• W4287248904 cites W2039713231 @default.
• W4287248904 cites W2076583826 @default.
• W4287248904 cites W2091237544 @default.
• W4287248904 cites W2095219849 @default.
• W4287248904 cites W2097607554 @default.
• W4287248904 cites W2142830692 @default.
• W4287248904 cites W2145216999 @default.
• W4287248904 cites W2146264128 @default.
• W4287248904 cites W2425644022 @default.
• W4287248904 cites W2497926742 @default.
• W4287248904 cites W2519510391 @default.
• W4287248904 cites W2558810449 @default.
• W4287248904 cites W2772350196 @default.
• W4287248904 cites W2788579413 @default.
• W4287248904 cites W2894993577 @default.
• W4287248904 cites W2916159667 @default.
• W4287248904 cites W2922550132 @default.
• W4287248904 cites W2948622224 @default.
• W4287248904 cites W2974621372 @default.
• W4287248904 cites W2997153796 @default.
• W4287248904 cites W3009493972 @default.
• W4287248904 cites W3027374344 @default.
• W4287248904 cites W4206445899 @default.
• W4287248904 cites W4212810717 @default.
• W4287248904 cites W4247910510 @default.
• W4287248904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33769850" @default.
• W4287248904 hasPublicationYear "2021" @default.
• W4287248904 type Work @default.
• W4287248904 citedByCount "5" @default.
• W4287248904 countsByYear W42872489042021 @default.
• W4287248904 countsByYear W42872489042022 @default.
• W4287248904 countsByYear W42872489042023 @default.
• W4287248904 crossrefType "journal-article" @default.
• W4287248904 hasAuthorship W4287248904A5013185975 @default.
• W4287248904 hasAuthorship W4287248904A5056528203 @default.
• W4287248904 hasAuthorship W4287248904A5073846586 @default.
• W4287248904 hasAuthorship W4287248904A5078803157 @default.
• W4287248904 hasAuthorship W4287248904A5083493729 @default.
• W4287248904 hasAuthorship W4287248904A5085357003 @default.
• W4287248904 hasConcept C126322002 @default.
• W4287248904 hasConcept C134018914 @default.
• W4287248904 hasConcept C207103383 @default.
• W4287248904 hasConcept C2775887513 @default.
• W4287248904 hasConcept C2777180221 @default.
• W4287248904 hasConcept C2779284873 @default.
• W4287248904 hasConcept C2779829264 @default.
• W4287248904 hasConcept C2781308992 @default.
• W4287248904 hasConcept C2909862629 @default.
• W4287248904 hasConcept C44249647 @default.
• W4287248904 hasConcept C555293320 @default.
• W4287248904 hasConcept C71924100 @default.
• W4287248904 hasConceptScore W4287248904C126322002 @default.
• W4287248904 hasConceptScore W4287248904C134018914 @default.
• W4287248904 hasConceptScore W4287248904C207103383 @default.
• W4287248904 hasConceptScore W4287248904C2775887513 @default.
• W4287248904 hasConceptScore W4287248904C2777180221 @default.
• W4287248904 hasConceptScore W4287248904C2779284873 @default.
• W4287248904 hasConceptScore W4287248904C2779829264 @default.
• W4287248904 hasConceptScore W4287248904C2781308992 @default.
• W4287248904 hasConceptScore W4287248904C2909862629 @default.
• W4287248904 hasConceptScore W4287248904C44249647 @default.
• W4287248904 hasConceptScore W4287248904C555293320 @default.
• W4287248904 hasConceptScore W4287248904C71924100 @default.
• W4287248904 hasIssue "4" @default.
• W4287248904 hasLocation W42872489041 @default.
• W4287248904 hasOpenAccess W4287248904 @default.
• W4287248904 hasPrimaryLocation W42872489041 @default.
• W4287248904 hasRelatedWork W2567011734 @default.
• W4287248904 hasRelatedWork W2900336056 @default.
• W4287248904 hasRelatedWork W2993091388 @default.
• W4287248904 hasRelatedWork W2997605969 @default.
• W4287248904 hasRelatedWork W3027734631 @default.
• W4287248904 hasRelatedWork W3066769783 @default.
• W4287248904 hasRelatedWork W3118371520 @default.
• W4287248904 hasRelatedWork W3175025381 @default.
• W4287248904 hasRelatedWork W3176713229 @default.
• W4287248904 hasRelatedWork W4381378361 @default.
• W4287248904 hasVolume "27" @default.
• W4287248904 isParatext "false" @default.
• W4287248904 isRetracted "false" @default.
• W4287248904 workType "article" @default.